Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | FPR2 | P25090 | 7/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | FPR1 | P21462 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10305175 | 1.00 | CHRM1 (0.44) | CHRM1FPR2MMP1MMP3NAMPT | |
| SCHEMBL5552607 | 0.82 | FPR2 (0.52) | CHRM1FPR2MMP1MMP3TSHR | |
| SCHEMBL4214360 | 0.82 | FPR2 (0.52) | CHRM1FPR2MMP1MMP3TSHR | |
| SCHEMBL4205338 | 0.82 | FPR2 (0.52) | CHRM1FPR2MMP1MMP3TSHR | |
| Hydrochloric Acid SCHEMBL4725522 | 0.81 | FPR2 (0.51) | CHRM1FPR2MMP1MMP3KDM4E | |
| SCHEMBL890153 | 0.77 | CYP3A4 (0.41) | TSHRKMT2A | |
| SCHEMBL10305158 | 0.76 | HRH2 (0.46) | CHRM1FPR2MMP1MMP3HPGD | |
| SCHEMBL10180336 | 0.76 | AKT1 (0.54) | CHRM1DPP4 | |
| SCHEMBL4213020 | 0.76 | AKT1 (0.54) | CHRM1DPP4 | |
| SCHEMBL4213022 | 0.76 | AKT1 (0.54) | CHRM1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288556-B2 | 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20090036436-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | ALLERGAN, INC. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036436-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | OPRL1, HCAR2, OPRM1 | CHRM1 229/4885FPR2 79/4885MMP1 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.